Objective To investigate the clinical efficacy and safety of concurrent chemoradiotherapy combined with Taixinsheng（tradename for nimotuzumab）in the treatment of advanced esophageal cancer.Methods A total of 106 patients with advanced esophageal cancer admitted to a hospital in Liaoning from October 2014 to July2015 were selected as subjects.Patients were divided into control group（n=66）and observation group（n=40）.Both groups were treated with chemotherapy combined with three-dimensional conformal radiotherapy

while observation group was treated with Taixinsheng in addition.The therapeutic effects of the two groups were compared at 3 days after treatment;the level of carcinoembryonic antigen（CEA）

high mobility protein B1（HMGB1）and squamous cell carcinoma antigen（SCC-Ag）were compared between the two groups before treatment and at 1 week after the treatment;at the time of discharge

the adverse reactions of the two groups were compared;the survival of the two groups was compared for 3 years.Results The objective response rate of the observation group was 92.50%

which was higher than that of the control group（77.27%）.The differences were statistically significant（χ2=4.096

P=0.043）.The disease control rate of the observation group and the control group were 100.00%and 95.45%

respectively

and the difference was not statistically significant（P

>

0.05）.At the end of treatment

the levels of CEA

HMGB1 and SCC-Ag in the observation group were（46.78±5.01）ng/mL

（104.12±11.26）ng/mL

（26.35±2.74）ng/mL

respectively

which were lower than those of the control group

which were（58.24±5.93）ng/mL

（134.15±14.38）ng/mL and（42.96±4.37）ng/mL;the difference was statistically significant（P

<

0.05）.The incidences of fever and rash in the observation group were57.5% and 65.0%

which were higher than those of the control group（30.3% and 21.2%）.The difference was statistically significant（χ

2

=7.641

20.324;P

<

0.05）.The 1-year survival rate of the observation group was72.50%

which was higher than that of the control group（57.58%）.The difference was statistically significant（χ

2

=4.254

P

<

0.05）.There was no significant difference in the 2-year survival rate and 3-year survival rate between the two groups（67.50% and 22.50%in the observation group

46.97%and 16.67%in the control group;P

>

0.05）.The median survival time was 29 months（95%CI:26.2 to 31.8）in the observation group and 19 months（95%CI:7.4 to 30.6）in the control group.Conclusion Concurrent chemoradiotherapy combined with Taixinsheng has a definite curative effect on advanced esophageal cancer.It can improve the objective remission rate

tumor marker level and the 1-year survival rate of patients with advanced esophageal cancer

and has a favorable safety profile.Thus

it is worthy of clinical application.